Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PERRIGO MANAGEMENT ACQUIRING PRIVATE LABEL MANUFACTURER FROM GROW

Executive Summary

PERRIGO MANAGEMENT ACQUIRING PRIVATE LABEL MANUFACTURER FROM GROW Group for $55.8 mil. in cash and short-term notes, Grow noted in a March 24 release. In connection with the sale, Grow said, $45.2 mil. of Perrigo's long-term debt will be eliminated from Grow's consolidated balance sheet. The net value of the deal for Grow in cash, notes and debt assumption will surpass $100 mil. Grow, a New York City-based manufacturer of private label household cleaning and industrial maintenance products, acquired L. Perrigo in January 1986 for approximately $45 mil. ("The Pink Sheet," Jan. 13, 1986, T&G-8). Grow financed the deal with long-term debt that it hoped to retire by spinning off 26% of Perrigo via a public offering last fall ("The Pink Sheet" Aug. 24, T&G-7). However, the timing of the offering could not have been less fortuitous. Perrigo management had been scheduled to meet with its underwriters to set a final price for the offering on "Black Monday," Oct. 19, 1987. As a result of the stock market crash, Grow and Perrigo had to cancel the stock offering. With the market for new offerings drying up after the crash, Grow was forced to consider other alternatives due to the continued effect of debt burden on its cash position. In a separate March 24 press release, Perrigo said the management team acquiring the OTC and H&BA private label manufacturer is led by Chairman Bill Swaney and President and CEO Mike Jandernoa, "with the participation and support of the management team." The management team taking Perrigo private again is essentially the same as the group that sold to Grow two years ago, with the exception of a Smith Barney venture capital group and a large shareholder that had supported the merger with Grow. Perrigo said that this time around it will have a "different mix in terms of ownership." The transaction, Perrigo predicted, "will benefit both companies by allowing Grow to reduce a large portion of their debt and giving Perrigo the independence to finance its growth." The deal is scheduled to close on March 31. Perrigo is the leading private label manufacturer of OTC and health and beauty aid products in the U.S. The company supplies private label line items to a number of retailers including Rite Aid, K-Mart, and Safeway, and recently signed a long-term supply agreement with Peoples worth $40 mil. In 1987, Perrigo also announced plans to market its own Equate private label line. Perrigo sales in fiscal 1987 (ended June 30) were $130 mil.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS013421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel